

FIRST LIGHT

RESEARCH

BOB Economics Research | Wholesale Inflation WPI also inches up-Rate cut off the table

IndusInd Bank | Target: Rs 1,700 | +15% | BUY Asset quality amiss

Mindtree | Target: Rs 780 | -10% | SELL Impressive margin show but growth grounds weak ahead

SUMMARY

India Economics: Wholesale Inflation

WPI inflation edged up to 7-month high of 2.6% in Dec'19 from 0.6% in Nov'19 led by food inflation which rose to 11% in Dec'19 (9% in Nov'19). At the same time, deflation in fuel and power index and manufactured products eased. We see WPI inflation increasing further in the months ahead as upward momentum in food and energy prices continue. In the above backdrop, we believe RBI will remain vigilant but on hold as growth impulses remain weak. A rate cut will have to wait for inflation pressures to ease, perhaps in H2FY21.

Click here for the full report.

IndusInd Bank

IndusInd Bank's (IIB) Q3FY20 PAT grew 33% YoY to Rs 13bn, largely due to 34% YoY growth in NII and 5bps QoQ NIM expansion to 4.15%. Asset quality was a miss as slippages rose to ~Rs 19bn driven by three large corporate accounts worth Rs 7bn while SMA-2 loans stood at Rs 14bn (0.5% of loans). Exposure to three stressed groups declined to 0.5% of loans given recoveries and repayments. IIB made accelerated provisions worth Rs 2.5bn and raised its coverage on IL&FS exposure to 73% in Q3. We raise our TP to Rs 1,700 on roll over to Mar'21.

Click here for the full report.

15 January 2020

TOP PICKS

LARGE-CAP IDEAS				
Company	Rating	Target		
<u>Cipla</u>	Buy	570		
<u>ONGC</u>	Buy	210		
Petronet LNG	Buy	400		
Reliance Industries	Buy	1,860		
<u>TCS</u>	Add	2,230		

MID-CAP IDEAS

Company	Rating	Target
<u>Alkem Labs</u>	Buy	2,290
Future Supply	Buy	680
Greenply Industries	Buy	210
Laurus Labs	Buy	480
PNC Infratech	Buy	245
	1	

Source: BOBCAPS Research

DAILY MACRO INDICATORS

Indicator	Current	2D (%)	1M (%)	12M (%)
US 10Y yield (%)	1.85	Зbps	2bps	(86bps)
India 10Y yield (%)	6.60	1bps	(19bps)	(63bps)
USD/INR	70.86	0.1	(0.1)	0.1
Brent Crude (US\$/bbl)	64.20	(1.2)	(1.6)	8.8
Dow	28,907	0.3	2.7	20.9
Shanghai	3,116	0.8	5.0	22.9
Sensex	41,860	0.6	2.1	16.8
India FII (US\$ mn)	10 Jan	MTD	CYTD	FYTD
FII-D	(38.2)	(938.4)	(938.4)	2,005.7
FII-E	92.6	363.1	363.1	7,752.3

Source: Bank of Baroda Economics Research

BOBCAPS Research

research@bobcaps.in





Mindtree

Mindtree's (MTCL) Q3FY20 operating performance was buoyed by operating margin beat as revenue fell short on expectations. Soft deal wins, subpar digital business growth, top client dominated growth mix and moderation of quarterly annualized attrition characterized Q3FY20 operating metrics. Management is hopeful of sustaining growth momentum and operating margin improvement. We largely retain FY21/22 EPS estimates and reiterate SELL, rolling over to Dec'20 TP of Rs 780 (V/s Rs690 earlier).

Click here for the full report.



WHOLESALE INFLATION

WPI also inches up-Rate cut off the table

WPI inflation edged up to 7-month high of 2.6% in Dec'19 from 0.6% in Nov'19 led by food inflation which rose to 11% in Dec'19 (9% in Nov'19). At the same time, deflation in fuel and power index and manufactured products eased. We see WPI inflation increasing further in the months ahead as upward momentum in food and energy prices continue. In the above backdrop, we believe RBI will remain vigilant but on hold as growth impulses remain weak. A rate cut will have to wait for inflation pressures to ease, perhaps in H2FY21.

Food prices spike: In-line with sharp acceleration in food CPI inflation, even WPI food inflation soared to more than 6-year high of 11% in Dec'19 (9% in Nov'19). Vegetable prices at wholesale level increased by 69.7% in Dec'19 (45.3% in Nov'19) compared with 60.5% increase seen at retail level. Within vegetables, uptick in onion prices accelerated further to 455.8% in Dec'19 from 172.3% in Nov'19. On the other hand, cereal inflation eased marginally to 7.7% in Dec'19 compared with 7.9% in Nov'19 as prices of paddy decelerated (4% in Dec'19 vs 4.2% in Nov'19). Pulses prices also moderated to 13.1% in Dec'19 (16.6% in Nov'19). Prices of protein based items such as milk and eggs increased by 2.6% and 7.9% respectively in Dec'19.

Fuel inflation feeling upward pressure: Fuel and power inflation fell by (-) 1.5% in Dec'19 compared with (-) 7.3% in Nov'19. The sharp decline in the pace of contraction was driven by higher oil and coal prices. Coal prices inched by 2.5% in Dec'19 versus 1.1% in Nov'19. Mineral oil index contracted by only (-) 3.2% versus (-) 13.2% in Nov'19. International oil prices had risen by 12.6% on a YoY basis in Dec'19 compared with (-) 4.9% decline in Nov'19. In Jan'20 as well, international oil prices remain higher (+13.7% MTD), indicating build-up of price pressure.

Deflation in core eases: Deflation in core moderated to (-) 1.5% in Dec'19 from (-) 1.9% in Nov'19. Manufactured inflation dropped to (-) 0.3% in Dec'19 from (-) 0.8% in Nov'19. Of the 22 commodities, 10 witnessed upward momentum in prices led by pharma, basic metals and computer & electronic products. On the other hand, prices of other manufacturing products, furniture and printing declined steeply. The decline in international commodity prices too eased in Dec'19 on a YoY basis to (-) 1.9% from (-) 6.7% in Nov'19. In Jan'20 the decline in prices has eased further to (-) 1.3%.

14 January 2020

Sameer Narang Jahnavi | Sonal Badhan chief.economist@bankofbaroda.com





BUY TP: Rs 1,700 | A 15%

INDUSIND BANK

Banking

Asset quality amiss

IndusInd Bank's (IIB) Q3FY20 PAT grew 33% YoY to Rs 13bn, largely due to 34% YoY growth in NII and 5bps QoQ NIM expansion to 4.15%. Asset quality was a miss as slippages rose to ~Rs 19bn driven by three large corporate accounts worth Rs 7bn while SMA-2 loans stood at Rs 14bn (0.5% of loans). Exposure to three stressed groups declined to 0.5% of loans given recoveries and repayments. IIB made accelerated provisions worth Rs 2.5bn and raised its coverage on IL&FS exposure to 73% in Q3. We raise our TP to Rs 1,700 on roll over to Mar'21.

Slippages mount: Two accounts in the HFC (investment book) and travel sectors were proactively termed as NPAs post detection of fraud. IIB routed Rs 2.4bn (25%) provisions on these accounts via P&L in Q3 and the balance (75%) were drawn down from the reserves which shall be later debited to P&L equally over the next 3 quarters. This apart a paper/diversified group (subsequently recovered) account worth Rs 1.8bn/Rs 2.5bn too slipped into NPA.

IIB raised its coverage on IL&FS exposure to 73% and expects its exposures in tunnel/road project SPVs to be resolved in Q4. SMA-2 exposure stands at Rs 14bn (0.5% of loans) vs Rs 11bn (0.6%) in Q2.

Loan growth moderates further: IIB's loan growth at <20% YoY continues to moderate largely due to subdued 8% corporate loan growth. The bank received repayments/recoveries worth Rs 70bn in the last three quarters and sold corporate loans Rs 15bn in Q3.

Maintain BUY with revised TP of Rs 1,700: We continue to value the stock at 2.3x FY22E P/BV as merger synergies are expected to raise ROE to ~19% by FY22E but raise our TP to Rs 1,700 (revised from Rs 1,550 earlier) on roll over to Mar'21.

KEY FINANCIALS

Y/E 31 Mar	FY18A	FY19P	FY20E	FY21E	FY22E
Net interest income	74,974	88,462	121,131	141,941	177,991
NII growth (%)	23.7	18.0	36.9	17.2	25.4
Adj. net profit (Rs mn)	36,060	33,011	54,079	69,042	89,751
EPS (Rs)	60.2	54.9	82.5	97.5	126.8
P/E (x)	24.6	27.0	18.0	15.2	11.7
P/BV (x)	3.8	3.4	2.9	2.4	2.0
ROA (%)	1.8	1.3	1.7	1.7	1.8
ROE (%)	16.2	13.1	17.2	17.2	18.7

Source: Company, BOBCAPS Research

14 January 2020

Vikesh Mehta

research@bobcaps.in

Ticker/Price	IIB IN/Rs 1,482
Market cap	US\$ 12.6bn
Shares o/s	603mn
3M ADV	US\$ 82.4mn
52wk high/low	Rs 1,834/Rs 1,188
Promoter/FPI/DII	17%/52%/31%
Source: NSE	

STOCK PERFORMANCE



Source: NSE





SELL TP: Rs 780 | ❤ 10%

MINDTREE

IT Services

Impressive margin show but growth grounds weak ahead

Mindtree's (MTCL) Q3FY20 operating performance was buoyed by operating margin beat as revenue fell short on expectations. Soft deal wins, subpar digital business growth, top client dominated growth mix and moderation of quarterly annualized attrition characterized Q3FY20 operating metrics. Management is hopeful of sustaining growth momentum and operating margin improvement. We largely retain FY21/22 EPS estimates and reiterate SELL, rolling over to Dec'20 TP of Rs 780 (V/s Rs690 earlier).

Operating margin beat: MTCL reported 1% QoQ cc growth in Dec'19 quaryter falling short on our estimate of 1.8% QoQ cc growth. However, operating margin beat rounded better than expected operating performance. EBIT margin at 12%, up 280bps QoQ, was ahead of our/consensus estimate of 130/150bps QoQ improvement. Higher other income and lower taxes further aided net profits resulting into ~31% beat on our estimate V/s ~13.5% beat on EBIT.

Weak deal wins and subpar Digital business growth: Deal wins for the quarter were soft at US\$ 207mn (-33% QoQ and -19% YoY) led by delay in client decision making. We highlight that seal win expiring in 1 year stood lowest since Sep'16 quarter impairing near-term growth visibility. Digital revenue contributed 38.2% revenues with mere 2.1% QoQ/13.6% YoY growth.

Top client skewed growth for yet another quarter: MTCL's top client continued to dominate growth with 13.9% QoQ dollar revenue growth. We highlight that over last 2 years MTCL's top client revenue concentration has inched up 650bps to 23.1%.

14 January 2020

Ruchi Burde

research@bobcaps.in

Ticker/Price	MTCL IN/Rs 864
Market cap	US\$ 2.0bn
Shares o/s	165mn
3M ADV	US\$ 8.2mn
52wk high/low	Rs 995/Rs 652
Promoter/FPI/DII	74%/11%/15%
Source: NSE	

STOCK PERFORMANCE



Source: NSE

KEY FINANCIALS

Y/E 31 Mar	FY18A	FY19A	FY20E	FY21E	FY22E
Total revenue (Rs mn)	54,628	70,215	76,826	84,822	95,259
EBITDA (Rs mn)	7,405	10,645	10,615	13,142	15,286
Adj. net profit (Rs mn)	5,701	7,542	6,067	7,690	9,268
Adj. EPS (Rs)	34.7	45.8	36.8	46.7	56.3
Adj. EPS growth (%)	39.5	32.1	(19.6)	26.8	20.5
Adj. ROAE (%)	21.4	24.9	17.4	19.8	21.2
Adj. P/E (x)	24.9	18.9	23.5	18.5	15.4
EV/EBITDA (x)	19.1	13.3	13.3	10.5	8.7

Source: Company, BOBCAPS Research





Disclaimer

Recommendations and Absolute returns (%) over 12 months

BUY - Expected return >+15%

ADD – Expected return from >+5% to +15%

REDUCE – Expected return from -5% to +5%

SELL – Expected return <-5%

Note: Recommendation structure changed with effect from 1 January 2018 (Hold rating discontinued and replaced by Add / Reduce)

Rating distribution

As of 31 December 2019, out of 83 rated stocks in the BOB Capital Markets Limited (BOBCAPS) coverage universe, 50 have BUY ratings, 18 are rated ADD, 9 are rated REDUCE and 6 are rated SELL. None of these companies have been investment banking clients in the last 12 months.

Analyst certification

Each of the analysts mentioned in this research report certify, with respect to the sections of the report for which they are responsible, that (1) all of the views expressed in this report accurately reflect his/her personal views about the subject company or companies and its or their securities, and (2) no part of his/her compensation was, is, or will be, directly or indirectly, related to the specific recommendation(s) or view(s) in this report. Analysts are not registered as research analysts by FINRA and are not associated persons of BOBCAPS.

Important disclosures

This product is a compilation of previously published research notes. To view the complete report along with the associated Analyst certifications and Company-specific disclosures, please click on the hyperlink accompanying each excerpt.

General disclaimers

BOBCAPS is engaged in the business of Institutional Stock Broking and Investment Banking. BOBCAPS is a member of the National Stock Exchange of India Limited and BSE Limited and is also a SEBI-registered Category I Merchant Banker. BOBCAPS is a wholly owned subsidiary of Bank of Baroda which has its various subsidiaries engaged in the businesses of stock broking, lending, asset management, life insurance, health insurance and wealth management, among others.

BOBCAPS's activities have neither been suspended nor has it defaulted with any stock exchange authority with whom it has been registered in the last five years. BOBCAPS has not been debarred from doing business by any stock exchange or SEBI or any other authority. No disciplinary action has been taken by any regulatory authority against BOBCAPS affecting its equity research analysis activities.

BOBCAPS has obtained registration as a Research Entity under SEBI (Research Analysts) Regulations, 2014, having registration No.: INH00000040 valid till 03 February 2020. BOBCAPS is also a SEBI-registered intermediary for the broking business having SEBI Single Registration Certificate No.: INZ000159332 dated 20 November 2017.

BOBCAPS prohibits its analysts, persons reporting to analysts, and members of their households from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. Additionally, BOBCAPS prohibits its analysts and persons reporting to analysts from serving as an officer, director, or advisory board member of any companies that the analysts cover.

Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein.

This material should not be construed as an offer to sell or the solicitation of an offer to buy any security in any jurisdiction where such an offer or solicitation would be illegal. We are not soliciting any action based on this material. It is for the general information of BOBCAPS's clients. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Before acting on any advice or recommendation in this material, clients should consider whether it is suitable for their particular circumstances and, if necessary, seek professional advice.

The price and value of the investments referred to in this material and the income from them may go down as well as up, and investors may realize losses on any investments. Past performance is not a guide for future performance, future returns are not guaranteed and a loss of original capital may occur. BOBCAPS does not provide tax advice to its clients, and all investors are strongly advised to consult with their tax advisers regarding any potential investment in certain transactions — including those involving futures, options, and other derivatives as well as non-investment-grade securities — that give rise to substantial risk and are not suitable for all investors. The material is based on information that we consider reliable, but we do not represent that it is accurate or complete, and it should not be relied on as such. Opinions expressed are our current opinions as of the date appearing on this material only. We endeavour to update on a reasonable basis the information discussed in this material, but regulatory, compliance, or other reasons may prevent us from doing so.

FIRST LIGHT



We and our affiliates, officers, directors, and employees, including persons involved in the preparation or issuance of this material, may from time to time have "long" or "short" positions in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein and may from time to time add to or dispose of any such securities (or investment). We and our affiliates may act as market makers or assume an underwriting commitment in the securities of companies discussed in this document (or in related investments), may sell them to or buy them from customers on a principal basis, and may also perform or seek to perform investment banking or advisory services for or relating to these companies and may also be represented in the supervisory board or any other committee of these companies.

For the purpose of calculating whether BOBCAPS and its affiliates hold, beneficially own, or control, including the right to vote for directors, one per cent or more of the equity shares of the subject company, the holdings of the issuer of the research report is also included.

BOBCAPS and its non-US affiliates may, to the extent permissible under applicable laws, have acted on or used this research to the extent that it relates to non-US issuers, prior to or immediately following its publication. Foreign currency denominated securities are subject to fluctuations in exchange rates that could have an adverse effect on the value or price of or income derived from the investment. In addition, investors in securities such as ADRs, the value of which are influenced by foreign currencies, effectively assume currency risk. In addition, options involve risks and are not suitable for all investors. Please ensure that you have read and understood the Risk disclosure document before entering into any derivative transactions.

In the US, this material is only for Qualified Institutional Buyers as defined under rule 144(a) of the Securities Act, 1933. No part of this document may be distributed in Canada or used by private customers in the United Kingdom.

No part of this material may be (1) copied, photocopied, or duplicated in any form by any means or (2) redistributed without BOBCAPS's prior written consent.

Other disclosures

BOBCAPS does not have any financial interest in the subject company. BOBCAPS does not have actual/beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

BOBCAPS is not engaged in any market making activities for the subject company.

BOBCAPS or its associates may have material conflict of interest at the time of publication of this research report.

BOBCAPS's associates may have financial interest in the subject company. BOBCAPS's associates may hold actual / beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

BOBCAPS or its associates may have managed or co-managed a public offering of securities for the subject company or may have been mandated by the subject company for any other assignment in the past 12 months.

BOBCAPS may have received compensation from the subject company in the past 12 months. BOBCAPS may from time to time solicit or perform investment banking services for the subject company. BOBCAPS or its associates may have received compensation from the subject company in the past 12 months for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory services in a merger or specific transaction. BOBCAPS or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months.